 Connection
Michelle Barron to Young Adult
This is a "connection" page, showing publications Michelle Barron has written about Young Adult.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.213 |
|
|
|
-
Azziz-Baumgartner E, Budd A, Lee JS, Iuliano AD, Ellington SR, Levine MZ, Zheng XY, Gubareva L, Adams K, DeCuir J, Bozio CH, Reed C, Kirby MK, Rambo-Martin B, Jones JM, Biggerstaff M, Garg S, Davis CT, Shimabukuro TT, Burns E, Kondor R, Olsen SJ, Dugan VG, Irving SA, Naleway AL, Dascomb K, Sheffield T, DeSilva MB, Tartof SY, Sy LS, Klein NP, Zerbo O, Grannis SJ, Dixon BE, Stockwell MS, Stephens AB, Ong TC, Barron MA, Ball SW, Weber ZA, Reeves EL, Ray CS. Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season. JAMA Netw Open. 2026 Jun 01; 9(6):e2618581.
Score: 0.018
-
Wiegand RE, Chickery S, Yang DH, Ball SW, DeSilva MB, Dascomb K, Irving SA, Natarajan K, Klein NP, Grannis SJ, Ong TC, Rowley EAK, Yates A, Zhuang Y, Wilson S, McEvoy CE, Essien IJ, Akinsete OO, Naleway AL, Koppolu P, Zerbo O, Hansen JR, Jacobson KB, Block L, Dixon BE, Duszynski T, Rogerson C, Barron MA, Chavez C, Mak J, Ciesla AA, Godfrey M, Kautz A, Najdowski M, Link-Gelles R, DeCuir J, Payne AB. Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design. JAMA Netw Open. 2026 Jun 01; 9(6):e2625152.
Score: 0.018
-
Ciesla AA, Lazariu V, Watts JA, Vazquez-Benitez G, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva M, Sheffield T, Bride D, Van Otterloo J, Arndorfer J, Naleway AL, Koppolu P, Fireman B, Hansen J, Timbol J, Dixon BE, Rogerson C, Fadel W, Barron MA, Mayer D, Chavez C, Zhuang Y, Cheung A, Reichle L, Natarajan K, Payne AB, Link-Gelles R, Zerbo O. Effectiveness of 2023-2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women. Obstet Gynecol. 2026 Apr 01; 147(4):569-573.
Score: 0.018
-
Tenforde MW, Reeves EL, Weber ZA, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Yang DH, Grannis SJ, Irving SA, Ong TC, Link-Gelles R, Salas SB, Sy LS, Lewin B, Contreras R, Zerbo O, Fireman B, Hansen J, Timbol J, Sheffield T, Bride D, Arndorfer J, VanOtterloo J, McEvoy CE, Akinsete OO, Essien IJ, Dixon BE, Rogerson C, Fadel WF, Duszynski T, Naleway AL, Barron MA, Rao S, Mayer D, Chavez C, Ball SW, Payne AB, Ray C, Dickerson M, Neelam V, Adams K, Flannery B, DeCuir J, Garg S. Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023-2024 Season, United States. Clin Infect Dis. 2025 Oct 06; 81(3):667-678.
Score: 0.018
-
Reeves EL, Dascomb K, Irving SA, Klein NP, Tartof SY, Grannis SJ, Ong TC, Ball SW, Vazquez-Benitez G, Sheffield T, Bride D, Arndorfer J, Van Otterloo J, Naleway AL, Koppolu P, Zerbo O, Jacobson KB, Fireman BH, Hansen JR, Block L, Salas SB, Bezi C, Sy LS, Reyes IAC, Dixon BE, Fadel WF, Rogerson C, Duszynski T, Mayer D, Chavez C, Barron MA, Weber ZA, Yang DH, Cheung A, Payne AB, Link-Gelles R, Adams K, Neelam V, DeSilva MB, Natarajan K, Tenforde MW, DeCuir J, Ellington S, Olson SM. Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age. Vaccine. 2025 Aug 30; 62:127483.
Score: 0.017
-
Link-Gelles R, Chickery S, Webber A, Ong TC, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, Grannis SJ, Barron MA, Reese SE, McEvoy C, Sheffield T, Naleway AL, Zerbo O, Rogerson C, Self WH, Zhu Y, Lauring AS, Martin ET, Peltan ID, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker ME, Mohamed A, Johnson N, Steingrub JS, Khan A, Felzer JR, Duggal A, Wilson JG, Qadir N, Mallow C, Kwon JH, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Chappell JD, Halasa N, Johnson C, Natarajan K, Lewis NM, Ellington S, Reeves EL, DeCuir J, McMorrow M, Paden CR, Payne AB, Dawood FS, Surie D. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged =18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):73-82.
Score: 0.017
-
Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, Han J, McEvoy C, Ong TC, Naleway AL, Reese SE, Embi PJ, Dascomb K, Klein NP, Griggs EP, Liao IC, Yang DH, Fadel WF, Grisel N, Goddard K, Patel P, Murthy K, Birch R, Valvi NR, Arndorfer J, Zerbo O, Dickerson M, Raiyani C, Williams J, Bozio CH, Blanton L, Link-Gelles R, Barron MA, Gaglani M, Thompson MG, Fireman B. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022 10 03; 379:e072141.
Score: 0.014
-
Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, Han J, McEvoy C, Ong TC, Naleway AL, Reese SE, Embi PJ, Dascomb K, Klein NP, Griggs EP, Konatham D, Kharbanda AB, Yang DH, Fadel WF, Grisel N, Goddard K, Patel P, Liao IC, Birch R, Valvi NR, Reynolds S, Arndorfer J, Zerbo O, Dickerson M, Murthy K, Williams J, Bozio CH, Blanton L, Verani JR, Schrag SJ, Dalton AF, Wondimu MH, Link-Gelles R, Azziz-Baumgartner E, Barron MA, Gaglani M, Thompson MG, Fireman B. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
Score: 0.014
-
Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, DeSilva MB, Natarajan K, Yang DH, Rao S, Klein NP, Irving SA, Dixon BE, Dascomb K, Liao IC, Reynolds S, McEvoy C, Han J, Reese SE, Lewis N, Fadel WF, Grisel N, Murthy K, Ferdinands J, Kharbanda AB, Mitchell PK, Goddard K, Embi PJ, Arndorfer J, Raiyani C, Patel P, Rowley EA, Fireman B, Valvi NR, Griggs EP, Levy ME, Zerbo O, Porter RM, Birch RJ, Blanton L, Ball SW, Steffens A, Olson N, Williams J, Dickerson M, McMorrow M, Schrag SJ, Verani JR, Fry AM, Azziz-Baumgartner E, Barron M, Gaglani M, Thompson MG, Stenehjem E. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
Score: 0.013
-
Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, Dascomb K, Ong TC, Klein NP, Liao IC, Grannis SJ, Han J, Stenehjem E, Dunne MM, Lewis N, Irving SA, Rao S, McEvoy C, Bozio CH, Murthy K, Dixon BE, Grisel N, Yang DH, Goddard K, Kharbanda AB, Reynolds S, Raiyani C, Fadel WF, Arndorfer J, Rowley EA, Fireman B, Ferdinands J, Valvi NR, Ball SW, Zerbo O, Griggs EP, Mitchell PK, Porter RM, Kiduko SA, Blanton L, Zhuang Y, Steffens A, Reese SE, Olson N, Williams J, Dickerson M, McMorrow M, Schrag SJ, Verani JR, Fry AM, Azziz-Baumgartner E, Barron MA, Thompson MG, DeSilva MB. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
Score: 0.013
-
Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Moine P, Mueller SW. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. J Microbiol Immunol Infect. 2020 Apr; 53(2):321-327.
Score: 0.011
-
Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J, Mangino JE, Weber DM, Hebert CL, Marzec NS, Barron MA, Chaparro-Rojas F, Restrepo A, Hemmige V, Prasidthrathsint K, Cobb S, Herwaldt L, Raabe V, Cannavino CR, Hines AG, Bares SH, Antiporta PB, Scardina T, Patel U, Reid G, Mohazabnia P, Kachhdiya S, Le BM, Park CJ, Ostrowsky B, Robicsek A, Smith BA, Schied J, Bhatti MM, Mayer S, Sikka M, Murphy-Aguilu I, Patwari P, Abeles SR, Torriani FJ, Abbas Z, Toya S, Doktor K, Chakrabarti A, Doblecki-Lewis S, Looney DJ, David MZ. Bacterial and viral co-infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013-14. J Clin Virol. 2016 07; 80:12-9.
Score: 0.009
-
Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J, Mangino JE, Weber DM, Hebert CL, Marzec NS, Barron MA, Chaparro-Rojas F, Restrepo A, Hemmige V, Prasidthrathsint K, Cobb S, Herwaldt L, Raabe V, Cannavino CR, Hines AG, Bares SH, Antiporta PB, Scardina T, Patel U, Reid G, Mohazabnia P, Kachhdiya S, Le BM, Park CJ, Ostrowsky B, Robicsek A, Smith BA, Schied J, Bhatti MM, Mayer S, Sikka M, Murphy-Aguilu I, Patwari P, Abeles SR, Torriani FJ, Abbas Z, Toya S, Doktor K, Chakrabarti A, Doblecki-Lewis S, Looney DJ, David MZ. Severe Influenza in 33 US Hospitals, 2013-2014: Complications and Risk Factors for Death in 507 Patients. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1251-60.
Score: 0.009
-
Epson EE, Pisney LM, Wendt JM, MacCannell DR, Janelle SJ, Kitchel B, Rasheed JK, Limbago BM, Gould CV, Kallen AJ, Barron MA, Bamberg WM. Carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-ß-lactamase at an acute care hospital, Colorado, 2012. Infect Control Hosp Epidemiol. 2014 Apr; 35(4):390-7.
Score: 0.008
-
Pisney LM, Barron MA, Kassner E, Havens D, Madinger NE. Carbapenem-resistant Enterobacteriaceae rectal screening during an outbreak of New Delhi metallo-ß-lactamase-producing Klebsiella pneumoniae at an acute care hospital. Infect Control Hosp Epidemiol. 2014 Apr; 35(4):434-6.
Score: 0.008
-
Golightly LK, Barber GR, Barron MA, Page RL. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug Metabol Drug Interact. 2013; 28(1):49-58.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|